Sanofi-aventis and Exelixis have entered into a license agreement for XL147 and XL765 and a collaboration to develop inhibitors of phosphoinositide-3 kinase (PI3K) to treat cancer. Exelixis could receive over US$1 B if specific development and commercial milestones are achieved.